BioSpace News Archive

Bioasis Technologies Inc. announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended November 30, 2019.

Agilent Technologies Inc. announced that it is joining forces with the Indian Institute of Technology Delhi to promote biopharmaceutical research.

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announces that CytoSorb® is now approved and immediately available for the removal of the anti-platelet agent, ticagrelor, during surgery requiring cardiopulmonary bypass (CPB), with the achievement of European Union regulatory approval and CE Mark label expansion for this indication.

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors

New plan design from CVS Caremark eliminates member cost as a barrier to medication adherence without raising costs for benefits plan sponsors or increasing premiums or deductibles

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 4,830,917 of its common shares at a price to the public of $51.75 per share.

Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced the top-line preliminary results in the first patient in the company’s Pilot/Phase 1 study in the treatment of diverticulosis.

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761.

Agropur inc. and OptiBiotix® have partnered to bring SlimBiome®, a revolutionary ingredient that transforms the traditional approach to weight loss, to the North American market.